CORRECTION OF IRON DEFICIENCY IN CKD V HD PATIENTS WITH ANEMIA
Abstract
Hemodialysys results in loss of15-20 ml of blood or 5-7 mg of iron during each session or at least 1 g/ year. Additional iron may be lost through the gastrointestinal tract and during the menstruation in women. Excluding others possible reasons (genitourinary issues, laboratory investigations iron losses can amount minimum 1.7g per year). Dietary iron intake (0.5 – 1.0 g/year) only partially offsets iron deficit.
According to KDOQI Anemia Guidelines (2006), “the average iv iron needed to maintain a stable serum ferritin (SF) level and in that way neutral iron balance, appears to be range 22-65 mg/week; this amount corresponds with SFl > 200 mg/ at but the same time there is no sufficient evidence to recommend routine administration of iron if SF > 500 mg/l.
KDIGO Guidelines (2012) do not recommend routine use of iron supplementation in patients with transferrin saturation (TSAT) > 30% and SF > 500 mg/1.
Thereby the target SF and TSAT levels in CKD VD patients remain controversial and in practice are determined by specific clinical tasks requiring resolution: to increase hemoglobin level without erythropoiesis stimulating agents (ESA) administration, or to decrease ESA dose in its turn depends on specific patient’s iron status (absolute or functional iron deficit) and treatment period, – predialysis or dialysis.
Downloads
References
A Randomized Comparison of Ferumoxytol and Iron Sucrose for Treating Iron Deficiency Anemia in Patients with CKD/ Macdougall I., Strauss W., Mclaughlin J., [et al.] // CJASN. - 2014. - V 9. - P.705 - 712.
A randomized trial of intravenous and oral iron in chronic kidney disease/ Agarwal R, Kusek JW, Pappas MK.// Kidney Int. - 2015. - V. 88.
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease / Pfeffer M. A., Burdmann E. A., Chen C. Y., [et al.] // N Engl J Med. - 2009. - V. 361. - P. 2019-2032.
Considerations and challenges in defining optimal iron utilization in hemodialysis / Charytan D.M., Pai A.B., Chan C.T., [et al.] // J Am Soc Nephrol. - 2015. - V. 26. - P. 1238-1247.
Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality/ Bailie G.R., Larkina M., Goodkin D.A., [et al.] // Kidney Int. - 2015. - V. 87. - P. 162-168.
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial / Pisani A., Riccio E., Sabbatini M., [et al.] // Nephrol Dial Transplant. - 2015. - V. 30. - P. 645-652.
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia/ Macdougall I.C., Bock A.H., Carrera F. , [et al.] // Nephrol Dial Transplant . - 2014. - V. 29. - P. 2075-2084.
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis/ Rozen-Zvi B., Gafter-Gvili A., Paul M., [et al.] // Am J Kidney Dis. – 2008. – V. 52. - P. 897-906.
Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis/ Kuo K.L., Hung S.C., Liu J.S., [et al.] // Nephrology Dialysis Transplantation. – 2015. – Vol. 30, - P. 1518-1525
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease// KI. – 2012. – V. 2. – P. 279-335.
Oral or intravenous iron for anemia correction in chronic Kidney disease/ Drueke T.B., Massy Z.A.// KI. – 2015. – V. 88. – P. 673-676
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study/ Ponikowski P., Filippatos G., Colet J.C., [et al.] // Eur J Heart Fail. – 2015. – V. 17. – P. 329-339.
Parenteral versus oral iron for adults and children with chronic Kidney disease (Review). Abromki J., Hodson E.M., Craig J.C., Webster A.C. The Cochrane Library 2012, issue 1.
